本文選題：miR-221 + miR-222�。� 參考：《河北醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:甲狀腺癌是最常見的內(nèi)分泌系統(tǒng)的惡性腫瘤。在全球的發(fā)病率均呈不斷上升的趨勢(shì),是增長(zhǎng)速度最快的腫瘤之一。甲狀腺結(jié)節(jié)的良惡性判定及早期手術(shù)治療對(duì)患者取得良好預(yù)后具有關(guān)鍵性作用,因此尋找甲狀腺癌診斷的分子標(biāo)志物是目前研究的熱點(diǎn)。近年來(lái),多項(xiàng)研究發(fā)現(xiàn)miRNA與腫瘤的發(fā)生發(fā)展關(guān)系密切,并且mi RNA可通過(guò)多種靶基因調(diào)控甲狀腺癌的發(fā)生和發(fā)展。當(dāng)前的研究并不能完全解釋miR-221與miR-222在甲狀腺癌中的功能。本研究應(yīng)用實(shí)時(shí)熒光定量PCR法檢測(cè)甲狀腺癌組織及甲狀腺良性病變組織中mi R-221與miR-222的表達(dá)水平,分析其與臨床病理指標(biāo)之間關(guān)系,為研究甲狀腺癌的發(fā)生發(fā)展、診斷及治療提供新的思路。方法:1收集2014年7月-2016年7月河北醫(yī)科大學(xué)第一醫(yī)院甲狀腺手術(shù)標(biāo)本共65例。其中良性甲狀腺組織標(biāo)本38例,甲狀腺癌組織標(biāo)本27例。新鮮標(biāo)本離體后迅速置于液氮中保存。所有患者術(shù)前未接受任何放療及內(nèi)分泌治療。2采用實(shí)時(shí)熒光定量PCR法(quantitative real-time polymerase chain reaction,qRT-PCR)檢測(cè)miR-221與miR-222在甲狀腺癌組織及甲狀腺良性病變組織中的表達(dá)。3應(yīng)用SPSS 19.0軟件對(duì)實(shí)驗(yàn)的結(jié)果數(shù)據(jù)進(jìn)行統(tǒng)計(jì)分析。非正態(tài)分布的數(shù)據(jù)以P50(P25,P75)表示,對(duì)結(jié)果采用兩獨(dú)立樣本的非參數(shù)檢驗(yàn),P0.05為差異有統(tǒng)計(jì)學(xué)意義。結(jié)果:1 miR-221在21例結(jié)節(jié)性甲狀腺腫組織標(biāo)本中的表達(dá)量為0.028(0.008,0.165),在17例甲狀腺腺瘤組織中表達(dá)量為0.053(0.009,0.170),二者無(wú)明顯差異(P0.05)。miR-222在21例結(jié)節(jié)性甲狀腺腫組織標(biāo)本中的表達(dá)量為0.003(0.002,0.045),在17例甲狀腺腺瘤組織中表達(dá)量為0.008(0.002,0.041),二者無(wú)明顯差異(P0.05)。2 mi R-221在27例癌組織標(biāo)本中的表達(dá)量為3.155(0.137,55.796),高于38例甲狀腺良性病變組織中的0.030(0.007,0.162),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。miR-222在27例癌組織標(biāo)本中的表達(dá)量為0.065(0.014,0.212),高于38例甲狀腺良性病變組織中的0.006(0.002,0.038),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。3 miR-221與mi R-222的表達(dá)與患者的性別、年齡、臨床分期均無(wú)明顯相關(guān)性(P0.05);且miR-221與淋巴結(jié)轉(zhuǎn)移情況無(wú)明顯相關(guān)性(P0.05),而miR-222與淋巴結(jié)轉(zhuǎn)移情況相關(guān)(P0.05)。結(jié)論:1 miR-221與mi R-222在甲狀腺癌組織中高表達(dá),提示其與甲狀腺癌的發(fā)生有關(guān)。2 miR-221與mi R-222與甲狀腺良性病變的發(fā)生無(wú)明顯相關(guān)。3 miR-222可能與甲狀腺癌的進(jìn)展密切相關(guān)。
[Abstract]:Objective: thyroid carcinoma is the most common endocrine system malignant tumor. In the world, the incidence of disease is on the rise, is one of the fastest-growing tumors. The diagnosis of benign and malignant thyroid nodules and early surgical treatment are crucial for the patients to obtain a good prognosis. Therefore, the search for molecular markers for thyroid cancer diagnosis is a hot topic at present. In recent years, many studies have found that miRNA is closely related to tumorigenesis and progression, and mi RNA can regulate the occurrence and development of thyroid carcinoma through a variety of target genes. Current studies do not fully explain the role of miR-221 and miR-222 in thyroid cancer. In this study, the expression of miR-221 and miR-222 in thyroid carcinoma and benign thyroid lesions was detected by real-time fluorescence quantitative PCR, and the relationship between miR-221 and clinicopathological indexes was analyzed in order to study the occurrence and development of thyroid carcinoma. Diagnosis and treatment provide new ideas. Methods from July 2014 to July 2016, 65 thyroid specimens were collected from the first Hospital of Hebei Medical University. There were 38 cases of benign thyroid tissue and 27 cases of thyroid carcinoma. Fresh specimens were quickly stored in liquid nitrogen in vitro. The expression of miR-221 and miR-222 in thyroid carcinoma and benign thyroid lesions was detected by real-time quantitative real-time polymerase chain reaction.qRT-PCR.2 the expression of miR-221 and miR-222 in thyroid carcinoma and benign thyroid lesions was detected by SPSS 19.0 software. A statistical analysis of the result data is carried out. The data of non-normal distribution were expressed as P50 / P25 / P75), and there was significant difference between the two independent samples by non-parametric test (P0.05). Results the expression of 1 miR-221 in 21 cases of nodular goiter was 0.028 0. 008 ~ 0. 165%, and in 17 cases of thyroid adenoma was 0. 053 ~ 0. 009 ~ 0. 170%. There was no significant difference between them in the expression of P0. 05 and MIR-222 in 21 cases of nodular goiter, and the expression was 0. 0030. 002. 045% in 21 cases of nodular goiter. In 17 cases of thyroid adenoma, the expression level was 0.008 / 0.002 / 0.041. There was no significant difference in the expression of P0.052.MIR-221 in 27 cases of carcinoma, which was higher than 0.0300.0.0070.162in 38 cases of benign thyroid lesions. The difference was statistically significant in 27 cases of carcinoma. The expression level in tissue samples was 0.065 ~ 0.014 ~ 0.212%, which was higher than that in 38 cases of benign thyroid lesions. The difference was statistically significant between the expression of P0.05.3 miR-221 and mi R-222 and the sex of the patients. There was no significant correlation between age and clinical stage (P 0.05), and there was no significant correlation between miR-221 and lymph node metastasis (P 0.05), but there was no significant correlation between miR-222 and lymph node metastasis (P 0.05). Conclusion the high expression of miR-221 and miR-222 in thyroid carcinoma suggests that there is no significant correlation between R- and miR-221 in thyroid carcinogenesis and the occurrence of benign thyroid lesions. 3 miR-222 may be closely related to the progression of thyroid carcinoma.
【學(xué)位授予單位】：河北醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R736.1

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 徐升強(qiáng);;甲狀腺癌患者血漿miR-221的表達(dá)及臨床意義[J];中國(guó)實(shí)驗(yàn)診斷學(xué);2015年03期

2 龐新亞;高峰;權(quán)勝偉;;miRNA-221和miRNA-222在肝細(xì)胞肝癌中的表達(dá)及臨床意義[J];現(xiàn)代腫瘤醫(yī)學(xué);2014年12期

3 鄒文斌;李兆申;;中國(guó)胃癌發(fā)病率及死亡率研究進(jìn)展[J];中國(guó)實(shí)用內(nèi)科雜志;2014年04期

4 韓蘇軍;張思維;陳萬(wàn)青;李長(zhǎng)嶺;;中國(guó)前列腺癌發(fā)病現(xiàn)狀和流行趨勢(shì)分析[J];臨床腫瘤學(xué)雜志;2013年04期

5 郭曉東;熊璐;張紅萍;周艷賢;楊美;章方莉;劉樹紅;李進(jìn);;肝細(xì)胞癌肝移植患者血清miR-221檢測(cè)及其臨床意義[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2013年06期

6 ;甲狀腺結(jié)節(jié)和分化型甲狀腺癌診治指南[J];中國(guó)腫瘤臨床;2012年17期

7 張進(jìn);;前列腺癌組織miR-221和miR-222的表達(dá)及臨床意義[J];中國(guó)老年學(xué)雜志;2012年12期

8 陳建國(guó);;中國(guó)肝癌發(fā)病趨勢(shì)和一級(jí)預(yù)防[J];臨床肝膽病雜志;2012年04期

9 鄭榮壽;張思維;吳良有;李光琳;趙平;赫捷;陳萬(wàn)青;;中國(guó)腫瘤登記地區(qū)2008年惡性腫瘤發(fā)病和死亡分析[J];中國(guó)腫瘤;2012年01期

10 梅玫;任玉;周旋;祁艷斌;王鴻梅;張灝;申瀟詠;趙川;蘇征;姚智;;反義miR-221/222上調(diào)p27~(kip1)對(duì)MCF-7乳腺癌細(xì)胞系的放射增敏作用[J];中華乳腺病雜志(電子版);2009年06期

，

本文編號(hào)：1936294